U.S. markets close in 3 hours 54 minutes

Cronos Group Inc. (CRON)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.80-0.13 (-1.19%)
As of 12:05PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close10.93
Open11.50
Bid10.84 x 1400
Ask10.85 x 1000
Day's Range10.73 - 11.20
52 Week Range4.00 - 11.75
Volume2,727,507
Avg. Volume6,296,640
Market Cap3.879B
Beta (5Y Monthly)2.09
PE Ratio (TTM)37.63
EPS (TTM)0.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MarketWatch

    Aphria price target raised by Cantor to reflect merger with Tilray as analyst deems earnings disappointing

    Cantor Fitzgerald raised its 12-month stock price target for Canadian cannabis company Aphria Inc. to C$26 from C$11.75 on Friday, to factor in its merger with Tilray Inc. even though it was unimpressed by the company's quarterly earnings released on Thursday. "We were disappointed by the Nov qtr reported by APHA.TO on 1/14 (yes, the stock was up 20%, but we think other reasons were at play), but that would be like saying that President-elect Biden, VP-elect Harris, and just-elected Senators Warnock and Ossoff, all had a bad hair day," analyst Pablo Zuanic wrote in a note to clients. "They just won their respective elections. We think the analogy applies here - it is about what APHA + TLRY can do in a fast-deregulating cannabis world." Zuanic is expecting Canadian licensed players to have a first-mover advantage as recreational markets open in overseas markets, such as Israel, Mexico, Germany and the Netherlands, as medical markets develop and as they enter the U.S. "We raise these points because if Canopy Growth and Cronos [s:cron][ are valued at 18-21x CY21 EV/sales (based on FactSet consensus estimates), and APHA + TLRY is at 13x, despite being #1 in the Canadian market (20% share, 7pt above #2), and having the optionality of a future CPG partner (we think it is the most attractive asset), we would say there is value," he wrote. Aphria shares were up 7.5% premarket Friday, and have gained 131% in the last 12 months, while the Cannabis ETF has gained 31% and the S&P 500 has gained 15%.

  • Marijuana Stocks Jump On Democratic Senate; Are Any Good Buys Now?
    Investor's Business Daily

    Marijuana Stocks Jump On Democratic Senate; Are Any Good Buys Now?

    Marijuana stocks surged as a Democratic Senate adds to cannabis legalization momentum. Are any pot stocks good buys now amid profitability challenges?

  • Aphria Stock, Marijuana Stocks Rally On Sales Beat, But Analyst Cites These Concerns
    Investor's Business Daily

    Aphria Stock, Marijuana Stocks Rally On Sales Beat, But Analyst Cites These Concerns

    Aphria stock and other marijuana stocks jumped on Thursday, after the Canadian cannabis producer reported fiscal second-quarter revenue that beat expectations. The pot grower reported the results after it agreed to merge with rival Tilray — potentially creating a global weed-industry giant — and as more focus shifts to the U.S. and its legalization prospects. Aphria reported net sales of 160.5 million Canadian dollars, or around $126.57 million.